Iambic key facts
as of Oct 2026- Developer of an artificial intelligence-driven platform designed to address design problems in drug discovery, leveraging technology innovations.
- Iambic is valued at approximately $648.0M as of Oct 2026, set at its later-stage round, Apr 2026; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $354.8M across 2 recorded rounds; the latest was Early Stage VC ($38.4M) in Apr 2024.
- Notable investors include Alumni Ventures, Sequoia Capital, Coatue Management, Nvidia, Alexandria Venture Investments — 31 tracked in total.
- Iambic has filed 4 Form Ds with the SEC since 2023, most recently Jun 2024 ($38.4M sold to 11 investors).
- Status: Privately Held (backing).
Valued at $648.0M at its later-stage round, Apr 2026. Nothing has traded since.
- ·The complete investor list: 31 names
- ·Watch Iambic: the Monday email on marks, rounds and moves
Iambic funding rounds
2 roundsIambic leadership
- Michael SecoraChief Financial Officer & Corporate Development Officer
- Neil JosephsonChief Medical Officer
- Peter OlsonChief Scientific Officer
Who backs Iambic
31+Iambic valuation
Iambic was valued at $648 million at its later-stage round in Apr 2026. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Iambic raised?
Iambic has raised $355 million in total; 2 of its rounds are on record. The largest on record was a $38.4 million early-stage round in Apr 2024.
Iambic has filed 4 Form Ds with the SEC since 2023, most recently in Jun 2024 ($38.4 million sold to 11 investors).
Iambic investors
31 investors are on record for Iambic, including Alumni Ventures, Sequoia Capital, Coatue Management and Nvidia. By type, the record holds 10 venture capital firms and 2 asset managers. The early-stage round in Apr 2024 drew 11 investors.
Who runs Iambic
12 people are listed on the Iambic team: 3 executives and 9 board members, including Michael Secora (Chief Financial Officer) and Neil Josephson (Chief Medical Officer). 12 of them have a verified direct contact on file.
About Iambic
Developer of an artificial intelligence-driven platform designed to address design problems in drug discovery, leveraging technology innovations. The company's engine combines artificial intelligence-driven technology and automated synthetic development to design small-molecule therapeutics, enabling physicians to get molecular predictions with speed and accuracy.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2019
- Employees
- 142
- Website
- iambic.ai/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.